Fig 1: Kaplan–Meier curves for cumulative survival of the four groups, based on serum levels of ERBB2 and NRG4. (A) The group with elevated serum levels of both ERBB2 and NRG4 had a lower survival rate compared with that of the other groups (IV vs. II, p = 0.007; IV vs. I, III, p < 0.001). (B) Kaplan–Meier curves for cumulative recurrence for the four groups, based on serum levels of ERBB2 and NRG4. The group with elevated serum levels of both ERBB2 and NRG4 had a higher HCC recurrence compared with that of the groups with low serum NRG4 (IV vs. III, p = 0.030; IV vs. I, p = 0.002; IV vs. II, p = 0.840). (Abbreviations: ERBB2, erythroblastic leukemia viral oncogene homolog 2; NRG4, neuregulin 4; HCC, hepatocellular carcinoma).
Fig 2: Graphs (A–C) present the receiver operating characteristic curves for the prediction of 6-month mortality. (A) The single factors, such as ERBB2, NRG4, and MIG6, were compared to each other, and (B) multiplied values were also compared. Although the comparison between single factors and the comparison between multiplied values did not show a significant difference, (C) the product of ERBB2 and NRG4 with MIG6 (AUC 0.940)/without MIG6 (AUC 0.942) showed superior results in AUC compared to the results for alpha-fetoprotein (AUC 0.727). (ERBB2, erythroblastic leukemia viral oncogene homolog 2; NRG4, neuregulin 4; MIG6, mitogen-inducible gene 6; AUC, area under the curve; red dotted line in the figure, random classifier).
Supplier Page from Abcam for Human ErbB2 / HER2 ELISA Kit